



US 20210215673A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0215673 A1**  
(43) **Pub. Date: Jul. 15, 2021**  
**Laing et al.**(54) **WHOLE CELL ASSAYS AND METHODS****Publication Classification**(71) Applicant: **Celcuity Inc.**, Minneapolis, MN (US)(51) **Int. Cl.****G01N 33/50** (2006.01)**G01N 33/574** (2006.01)**G01N 27/02** (2006.01)(72) Inventors: **Lance Gavin Laing**, Orono, MN (US);  
**Brian Francis Sullivan**, Medina, MN  
(US)(52) **U.S. Cl.**CPC ..... **G01N 33/5011** (2013.01); **G01N 33/5044**  
(2013.01); **G01N 27/02** (2013.01); **G01N**  
**33/574** (2013.01)(21) Appl. No.: **17/193,891**(22) Filed: **Mar. 5, 2021**

(57)

**ABSTRACT**

The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.

**Related U.S. Application Data**

(63) Continuation of application No. 16/027,073, filed on Jul. 3, 2018, now Pat. No. 10,976,307, which is a continuation of application No. 15/192,280, filed on Jun. 24, 2016, now Pat. No. 10,041,934, which is a continuation of application No. 14/590,731, filed on Jan. 6, 2015, now Pat. No. 9,404,915, which is a continuation of application No. 13/494,618, filed on Jun. 12, 2012, now abandoned.